HEMOGLOBIN

Scope & Guideline

Decoding the mysteries of blood disorders.

Introduction

Welcome to your portal for understanding HEMOGLOBIN, featuring guidelines for its aims and scope. Our guidelines cover trending and emerging topics, identifying the forefront of research. Additionally, we track declining topics, offering insights into areas experiencing reduced scholarly attention. Key highlights include highly cited topics and recently published papers, curated within these guidelines to assist you in navigating influential academic dialogues.
LanguageEnglish
ISSN0363-0269
PublisherTAYLOR & FRANCIS LTD
Support Open AccessNo
CountryUnited States
TypeJournal
Convergefrom 1976 to 2024
AbbreviationHEMOGLOBIN / Hemoglobin
Frequency6 issues/year
Time To First Decision-
Time To Acceptance-
Acceptance Rate-
Home Page-
Address2-4 PARK SQUARE, MILTON PARK, ABINGDON OR14 4RN, OXON, ENGLAND

Aims and Scopes

The journal 'HEMOGLOBIN' primarily focuses on research related to hemoglobinopathies and thalassemia, providing a platform for the latest findings in genetic mutations, clinical management strategies, and treatment advancements. Its core areas include genetic studies, clinical trials, and innovative therapeutic approaches.
  1. Genetic and Molecular Characterization of Hemoglobin Variants:
    The journal publishes studies that explore the genetic basis of various hemoglobinopathies, including sickle cell disease and thalassemia, focusing on novel mutations and their implications for disease phenotype.
  2. Clinical Management and Treatment Approaches:
    Research on clinical practices, treatment efficacy, and management strategies for patients with hemoglobin disorders is a key focus, including studies on iron chelation therapy, hydroxyurea, and stem cell transplantation.
  3. Public Health and Screening Initiatives:
    The journal emphasizes public health strategies for screening and managing hemoglobin disorders, particularly in high-prevalence regions, aiming to reduce the burden of these diseases through early detection.
  4. Innovative Therapeutic Strategies:
    It highlights advancements in gene therapy, targeted treatments, and novel drug development aimed at improving patient outcomes for those suffering from hemoglobinopathies.
  5. Epidemiological Studies and Risk Factors:
    The journal frequently publishes epidemiological research that assesses the prevalence, risk factors, and comorbidities associated with hemoglobin disorders across different populations.
Recent publications in 'HEMOGLOBIN' indicate a clear trend towards innovative research themes that are gaining traction. These themes reflect the evolving landscape of hemoglobinopathy research, particularly in genetics and personalized medicine.
  1. Gene Therapy and Precision Medicine:
    There is a notable increase in studies focusing on gene therapy as a treatment for hemoglobin disorders, highlighting its potential to address the underlying genetic causes of diseases like sickle cell anemia and thalassemia.
  2. Utilization of Next-Generation Sequencing:
    The application of next-generation sequencing techniques to identify novel mutations and understand the genetic basis of hemoglobinopathies is becoming increasingly prominent in recent studies.
  3. Impact of COVID-19 on Hemoglobin Disorders:
    Research exploring the effects of COVID-19 on patients with hemoglobin disorders, including changes in disease management and outcomes, is an emerging area of interest.
  4. Quality of Life and Psychosocial Factors:
    There is a growing emphasis on studies that assess the quality of life and psychosocial factors affecting patients with hemoglobinopathies, reflecting a broader understanding of patient care.
  5. Novel Therapeutic Agents and Combination Therapies:
    Research into new therapeutic agents and combination treatments, particularly focusing on improving outcomes for patients with severe forms of hemoglobin diseases, is gaining momentum.

Declining or Waning

While 'HEMOGLOBIN' maintains a robust focus on various aspects of hemoglobinopathies, certain themes appear to be declining in prominence based on recent publications. This may reflect shifts in research priorities or advancements in understanding that have made some topics less central.
  1. Historical Perspectives on Thalassemia:
    Research focusing on historical accounts or retrospective studies of thalassemia has seen a decline, possibly due to a shift towards more contemporary clinical trials and genetic studies.
  2. Basic Hematological Studies:
    Papers that primarily report basic hematological parameters without a direct link to clinical outcomes or genetic insights seem to be less frequent, as the field moves towards more applied research.
  3. Global Comparisons of Thalassemia Management:
    While still relevant, comparative studies between different countries regarding thalassemia management strategies have become less common, likely as institutions focus more on localized and personalized medicine approaches.
  4. Older Diagnostic Techniques:
    The use of older diagnostic methods, such as simple electrophoresis without advanced sequencing, appears to be waning as new technologies like next-generation sequencing gain prominence.
  5. General Reviews without Novel Insights:
    The publication of general reviews that do not provide novel insights or applications related to hemoglobinopathies is declining, as the journal favors studies that contribute new knowledge or advancements in treatment.

Similar Journals

Clinical Genitourinary Cancer

Transforming insights into clinical practice.
Publisher: CIG MEDIA GROUP, LPISSN: 1558-7673Frequency: 6 issues/year

Clinical Genitourinary Cancer, published by CIG MEDIA GROUP, LP, is a leading journal in the fields of Oncology and Urology, with an impressive impact reflected in its quartile rankings (Q2 in Oncology and Q1 in Urology for 2023) and strong Scopus rankings (22nd in Urology and 162nd in Oncology). The journal aims to innovate and inspire new research in genitourinary malignancies, providing a platform for the latest findings in diagnosis, treatment, and patient management. With its commitment to high-quality publications since its establishment in 2005, Clinical Genitourinary Cancer serves a crucial role in advancing the understanding of these complex conditions and enhancing clinical practices. Researchers, professionals, and students in the medical community are encouraged to engage with this essential resource, which facilitates open access to pioneering studies that drive the field forward.

CANCER GENE THERAPY

Innovating Genetic Solutions for Oncology
Publisher: SPRINGERNATUREISSN: 0929-1903Frequency: 12 issues/year

Cancer Gene Therapy, published by SpringerNature, stands at the forefront of research in the fields of cancer research, molecular biology, and molecular medicine. With a robust impact factor reflecting its significant influence—ranking in the Q2 category for cancer research and Q1 for both molecular biology and molecular medicine—it serves as an essential resource for scholars and practitioners alike. Since its inception in 1994, the journal has dedicated itself to advancing the understanding and therapeutic application of genetic innovations in oncology. Notably, it holds distinguished Scopus ranks, placing it among the top tier journals in its categories, underscoring its importance to the scientific community. While open access options are not available, the compelling research published here offers invaluable insights into the latest advancements and strategies in cancer therapy. Engaging with *Cancer Gene Therapy* not only keeps professionals informed but also inspires future innovations in the quest for effective cancer treatments.

Cancer Research and Treatment

Connecting science and healing in cancer care.
Publisher: KOREAN CANCER ASSOCIATIONISSN: 1598-2998Frequency: 4 issues/year

Cancer Research and Treatment is a premier academic journal published by the Korean Cancer Association that focuses on advancing scientific knowledge and clinical practices in the fields of cancer research and oncology. With an ISSN of 1598-2998 and an E-ISSN of 2005-9256, the journal showcases cutting-edge research articles, clinical trials, and comprehensive reviews that address the multifaceted challenges in cancer treatment and management. Published in South Korea, this journal has established itself as a critical resource, evidenced by its Q1 rank in Oncology and Q2 rank in Cancer Research, reflecting its influence and stature within the academic community. The impact of research disseminated through Cancer Research and Treatment is underscored by its significant percentile rankings in Scopus, with notable positions in both the pharmaceutical and biological sectors. This journal aims to bridge the gap between laboratory research and clinical application, providing a platform for researchers, healthcare professionals, and students to enhance their understanding of cancer-related innovations and therapeutic strategies. Readers will benefit from rich content that not only discusses the latest advancements but also engages with pressing global health issues related to cancer.

PARKINSONISM & RELATED DISORDERS

Shaping the dialogue on neurodegenerative diseases.
Publisher: ELSEVIER SCI LTDISSN: 1353-8020Frequency: 12 issues/year

PARKINSONISM & RELATED DISORDERS, published by Elsevier Science Ltd, is a prominent peer-reviewed journal dedicated to advancing the understanding of Parkinson's disease and related neurodegenerative disorders. With an impact factor placing it in the Q2 category across multiple fields including Geriatrics and Gerontology and Neurology for 2023, this journal serves as a crucial platform for researchers, healthcare professionals, and students alike. Covering an array of topics from clinical trials to innovative therapeutic strategies, it aims to disseminate valuable insights that can improve patient care and outcomes. While it remains a subscription-based journal, its relevance is underscored by its consistent rankings in Scopus, where it ranks 105th in Clinical Neurology and 35th in Geriatrics and Gerontology. Authored by top scholars in the field, PARKINSONISM & RELATED DISORDERS continues to contribute significantly to the body of knowledge surrounding these debilitating conditions, facilitating the exchange of cutting-edge research and fostering collaboration within the scientific community.

CONGENITAL ANOMALIES

Illuminating insights into congenital disorders.
Publisher: WILEYISSN: 0914-3505Frequency: 4 issues/year

CONGENITAL ANOMALIES is a notable journal published by WILEY, dedicated to advancing the understanding of congenital disorders and anomalies through high-quality research and clinical insights. With an ISSN of 0914-3505 and an E-ISSN of 1741-4520, this journal has been a key resource for professionals in the fields of pediatrics, embryology, and developmental biology since its inception in 1973, although coverage discontinued in Scopus after 2019 due to evolving standards in publication. The journal is ranked in the 48th percentile in the domain of pediatrics, as well as in the 26th and 14th percentiles respectively for embryology and developmental biology, placing it among respected publications in its category. Although it does not currently offer open access options, its contributions remain vital for researchers, healthcare professionals, and students seeking up-to-date information on congenital anomalies, their origins, and potential interventions. With a commitment to fostering knowledge in this critical area of health science, CONGENITAL ANOMALIES continues to play an important role in the intersection of scientific research and clinical practice.

Thalassemia Reports

Fostering collaboration for thalassemia solutions.
Publisher: MDPIISSN: 2039-4357Frequency: 4 issues/year

Thalassemia Reports is a distinguished journal dedicated to the field of hematology, focusing on the implications, management, and advancements related to thalassemia and related disorders. Published by MDPI, a renowned open-access publisher, this journal has been committed to disseminating high-quality research since its inception in 2011. With an ISSN of 2039-4357 and an E-ISSN of 2039-4365, it serves as an invaluable resource for researchers, clinicians, and students alike who are engaged in the study of hemoglobinopathies. The journal fosters easy access to peer-reviewed articles that contribute to the understanding and management of thalassemia, thus promoting collaborative efforts within the academic and medical communities. The open-access model ensures that critical findings are widely available to the global audience, enhancing knowledge exchange and innovation in the field.

Mediterranean Journal of Hematology and Infectious Diseases

Unlocking insights in hematology and infectious diseases for global health.
Publisher: MATTIOLI 1885ISSN: Frequency: 1 issue/year

Mediterranean Journal of Hematology and Infectious Diseases is a distinguished open access journal published by MATTIOLI 1885, dedicated to advancing the field of hematology and infectious diseases. Since its inception in 2009, the journal has provided a platform for researchers and practitioners to disseminate innovative findings, foster scholarly discourse, and enhance our understanding of these critical medical disciplines. With an impact factor reflecting its scholarly influence, it is recognized in the Q3 quartile for both Hematology and Infectious Diseases categories as of 2023. The journal's commitment to open access ensures that high-quality research is accessible to a global audience, contributing to the improvement of clinical practices and public health. Located in Fidenza, Italy, the journal continues to support converged research efforts from 2010 to 2024, making it an essential resource for academics, clinicians, and students in the medical community.

LEUKEMIA

Championing Excellence in Cancer Research
Publisher: SPRINGERNATUREISSN: 0887-6924Frequency: 12 issues/year

LEUKEMIA, published by SpringerNature, is a premier journal in the field of hematology and oncology, with ISSN 0887-6924 and E-ISSN 1476-5551. Established in 1987, this esteemed publication serves as a critical platform for disseminating groundbreaking research and comprehensive reviews on the pathophysiology, diagnosis, and treatment of leukemia and related hematological disorders. With a distinguished impact, it holds a top-tier status in several categories, including Q1 rankings in Anesthesiology and Pain Medicine, Cancer Research, Hematology, and Oncology for 2023. The journal is globally recognized for its rigorous peer-review process and is highly regarded among academia, evidenced by its impressive Scopus rankings—7th in Hematology and 24th in Oncology. Researchers, clinicians, and students alike will benefit from the rich content that this journal offers, making it an invaluable resource in the fight against leukemia. The main objective of LEUKEMIA is to advance knowledge and encourage further innovations within the field, ensuring that vital insights reach practitioners and researchers around the world.

Molecular Genetics & Genomic Medicine

Advancing the frontiers of genomic medicine.
Publisher: WILEYISSN: 2324-9269Frequency: 12 issues/year

Molecular Genetics & Genomic Medicine, published by WILEY, is an esteemed and open-access journal that has been a prominent source of knowledge in the fields of genetics and molecular biology since its establishment in 2013. With an ISSN of 2324-9269, it aims to provide a platform for the dissemination of novel findings and innovative research that pushes the boundaries of genomics and its clinical applications. The journal holds a Q3 categorization in Genetics, Clinical Genetics, and Molecular Biology, reflecting its growing influence in these disciplines, as evidenced by its Scopus rankings. Researchers, professionals, and students alike will find valuable insights and advancements in genomic medicine, making this journal an essential resource for those dedicated to the understanding and application of genetic and molecular research in healthcare. Located at 111 River St, Hoboken, NJ, Molecular Genetics & Genomic Medicine continues to foster a global dialogue within the scientific community, ensuring accessible knowledge for all.

Clinical Pediatric Endocrinology

Fostering a community dedicated to improving pediatric endocrine care.
Publisher: JAPANESE SOC PEDIATRIC ENDOCRINOLOGYISSN: 0918-5739Frequency: 4 issues/year

Clinical Pediatric Endocrinology is a prestigious journal dedicated to advancing the field of pediatric endocrinology, published by the Japanese Society of Pediatric Endocrinology. With a respectable ISSN 0918-5739 and E-ISSN 1347-7358, this journal serves as a critical platform for innovative research spanning various aspects of endocrine disorders in children, including diabetes and metabolic conditions. Although it does not currently offer open access, it remains highly relevant in its category, being ranked in Q4 and Q3 tiers across multiple specialties as of 2023. With a publication history that spans from 1992 to 2024, this journal has contributed significantly to the literature, as evidenced by its inclusion in prominent databases. It invites submissions from researchers and practitioners worldwide, aiming to facilitate knowledge sharing and improve clinical practices in pediatric endocrinology. For those dedicated to enhancing care outcomes in children with endocrine disorders, Clinical Pediatric Endocrinology provides essential insights and fosters a community of engaged professionals.